Latest news
Merck (NYSE:MRK): Can new products offset the coming patent cliff? - Kalkine MediaKalkine Media · Fri, 07 Aug 2026 16:59:00 GMTCan Merck (NYSE:MRK) Offset The Coming Keytruda Patent Cliff? - Kalkine MediaKalkine Media · Thu, 06 Aug 2026 19:29:00 GMTBeyond the Crop Protection Patent Cliff: How Competitive Advantage Shifts After Patent Expiration - AgriBusiness GlobalAgriBusiness Global · Thu, 06 Aug 2026 16:27:53 GMTPfizer's Diversified Portfolio Shields It From Significant Cash Flow Declines During Patent Cliffs - MorningstarMorningstar · Tue, 04 Aug 2026 18:44:36 GMTAs portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger - BioSpaceBioSpace · Tue, 04 Aug 2026 14:01:05 GMTThe Patent Cliff and the Drug Market’s Innovation Cycle - The American Action ForumThe American Action Forum · Tue, 04 Aug 2026 13:37:06 GMTGSK prepares for patent cliff with $2.5B cost-cutting plan - BioPharma DiveBioPharma Dive · Tue, 28 Jul 2026 07:00:00 GMTThe patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO says - Endpoints NewsEndpoints News · Mon, 27 Jul 2026 07:00:00 GMT